Lloyd Minor
Showing 1–3 of 3 transcripts.
- Milken Institute59 min
Longevity Lab: Can You Live to 100? | Global Conference 2024
Allison Aubrey, James Bethell, Dan Buettner, Peter Diamandis, Kristen Fortney, Lloyd Minor
A panel of scientists and policymakers discusses converging strategies to achieve longevity escape velocity through the integration of AI-driven biotech, emerging drugs like rapamycin and GLP-1 agonists, and preventative Blue Zone principles that emphasize environmental design over individual willpower. With the XPRIZE Healthspan Competition challenging teams to reverse functional aging within a decade and healthcare systems pivoting from sick care to community-based prevention, the dialogue highlights a transition toward treating aging as a manageable biological process rather than an inevitable decline. While optimistic projections suggest widespread adoption of anti-aging therapies within twenty years, experts caution that true success requires balancing pharmacological interventions with social determinants of health to ensure extended healthspan alongside increased lifespan.
- Milken Institute59 min
Artificial Intelligence and Machine Learning in Medicine: Hope or Hype?
Rick Berke, Rowan Chapman, Iya Khalil, Lloyd Minor, George Yancopoulos, Megan Zweig, Dan Furstenberg
Industry leaders and researchers convened to address the critical bottleneck of poor data quality in healthcare AI, noting that high-quality "big data" is essential for overcoming the limitations of existing Electronic Health Records and avoiding failures like those seen with IBM Watson. While venture capital has pivoted from high-risk clinical decision support to near-term applications in operational efficiency and medical imaging, participants advocated for long-term systemic reforms such as FDA mandates for molecular data collection and a $200 million biobank initiative to enable precise patient phenotyping. The panel concluded that bridging the gap between clinical trial success and real-world outcomes requires rigorous regulatory frameworks and collaborative investment to reduce physician burnout and improve drug development success rates.
- Milken Institute1h 3m
The Search for Cures Leads to Silicon Valley
Lindy Fishburne, Linda Avey, Noah Craft, Lloyd Minor, Asha Nayak, Lisa Suennen, Asha Rogers, Martha Minow, Male Speaker 2, Brody
Hosted by Lindy Fishburne, a panel of leaders from Intel, Stanford Medicine, 23andMe, and Science 37 discussed the strategic shift from reactive sick care to proactive precision health through decentralized data models and consumer engagement. Initiatives such as Intel's Collaborative Cancer Cloud, Stanford's genomic-phenotypic integration, and Science 37's patient-centric trials aim to dismantle data silos while accelerating drug discovery and increasing trial diversity. The dialogue further emphasized that sustainable innovation requires overcoming reimbursement barriers and establishing patient data sovereignty to enable real-world evidence generation.